한글목차

약제 요약

CVN-424는 파킨슨병 치료제로 개발중인 신규 표적(GPR6)에 작용하는 퍼스트 인 클래스 경구용 비도파민성 화합물입니다. 파킨슨병과 관련된 D2 수용체 의존적 간접 경로를 선택적으로 표적화하여 현재 파킨슨병의 표준치료제인 레보도파와 뇌심부자극요법의 효과를 부작용 없이 얻을 수 있도록 하는 것을 목표로 하고 있습니다. 유의미한 유효성을 확인하였습니다. 회사는 2023년 2분기에 레보도파로 치료받지 않은 파킨슨병 환자를 대상으로 CVN424를 단독요법으로 평가하는 2상 개념증명 임상을 시작할 예정이며, 보조요법으로 승인받기 위해 추가적으로 CVN424를 평가하기 위한 임상 2상/III 임상을 시작할 예정입니다. 임상 II/III상 시험에 착수할 예정입니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 파킨슨병용 CVN-424에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 파킨슨병에서의 CVN-424 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 CVN-424 시장 평가

• 파킨슨병에서 CVN-424의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장 파킨슨병용 CVN-424의 시장 규모
• 시장 분석 : 국가별
  • 미국의 파킨슨병용 CVN-424의 시장 규모
  • 독일의 파킨슨병용 CVN-424의 시장 규모
  • 영국의 파킨슨병용 CVN-424의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"CVN-424 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about CVN-424 for Parkinson's disease in the seven major markets. A detailed picture of the CVN-424 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CVN-424 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CVN-424 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

CVN-424, Cerevance's lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6) in development for the treatment of Parkinson's disease. It selectively targets the D2 receptor-dependent, indirect pathway associated with Parkinson's disease and is intended to generate the positive effects of levodopa and deep brain stimulation, the current standard of care for Parkinson's disease, without the adverse effects. CVN424 demonstrated significant and clinically meaningful efficacy in a Phase II study in patients with Parkinson's disease. Additionally, the company planned to initiate a Phase II proof of concept study assessing CVN424 as a monotherapy treatment in patients with newly diagnosed Parkinson's disease not yet treated with levodopa in Q2 2023 and Phase II/III clinical study to further assess the drug with intentions of seeking regulatory approval as an adjunctive therapy.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CVN-424 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on CVN-424 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CVN-424 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CVN-424.
• The report contains forecasted sales of CVN-424 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for CVN-424 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CVN-424 Analytical Perspective by DelveInsight

• In-depth CVN-424 Market Assessment

This report provides a detailed market assessment of CVN-424 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• CVN-424 Clinical Assessment

The report provides the clinical trials information of CVN-424 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CVN-424 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to CVN-424 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CVN-424 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of CVN-424 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CVN-424 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of CVN-424?
• What is the clinical trial status of the study related to CVN-424 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CVN-424 development?
• What are the key designations that have been granted to CVN-424 for Parkinson's disease?
• What is the forecasted market scenario of CVN-424 for Parkinson's disease?
• What are the forecasted sales of CVN-424 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to CVN-424 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. CVN-424 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CVN-424 Market Assessment

• 5.1. Market Outlook of CVN-424 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of CVN-424 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of CVN-424 in the United States for Parkinson's disease
  • 5.3.2. Market Size of CVN-424 in Germany for Parkinson's disease
  • 5.3.3. Market Size of CVN-424 in France for Parkinson's disease
  • 5.3.4. Market Size of CVN-424 in Italy for Parkinson's disease
  • 5.3.5. Market Size of CVN-424 in Spain for Parkinson's disease
  • 5.3.6. Market Size of CVN-424 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of CVN-424 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options